Azenta, Inc. (AZTA) Stock Analysis and Metrics

Azenta

NASDAQ: AZTA

$27.39 ▼ -0.91 (-3.22%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.26 Bn

P/E-17.36

P/S1.69

Div. Yield0.00

Revenue Growth (1y) (Qtr)104.72

Add ratio to table…

About

Azenta, Inc. is a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The company supports customers from research and clinical development through commercialization with sample management and automated storage systems as well as genomic services expertise. It offers a broad portfolio that includes sample procurement automated storage systems genomic services sample consumables informatics and data software and sample repository services. Azenta employs approximately 3000 full time part time and contingent workers worldwide and has sales in about 95 countries. Headquartered in Burlington Massachusetts the company operates in North America Asia and Europe.

Azenta generates revenue primarily from the sale of products and services in its two operating segments. The Sample Management Solutions segment sells automated storage systems cryogenic systems consumables instruments controlled rate thawing devices and offers sample repository services including on site and off site storage cold chain logistics bio processing disaster recovery and informatics solutions. The Multiomics segment provides genomic services such as gene sequencing gene synthesis bioinformatics and good laboratory practice regulatory services. Sales are made through a direct sales force for larger systems and services and through distributors for consumables and instruments in emerging markets.

The company operates through the following segments.

• The Sample Management Solutions segment operates as a single business unit offering end to end sample management products and services including Sample Repository Services and Core Products such as Automated Stores Cryogenic Systems Automated Sample Tubes Consumables and Instruments and Controlled Rate Thawing Devices. It provides customers with high level sample quality security availability intelligence and integrity throughout the sample lifecycle delivering complete cold chain of custody capabilities. The segment also offers expert consultation services for experimental design and implementation. Sample Repository Services include on site and off site sample storage cold chain logistics sample transport and collection relocation bio processing solutions disaster recovery and business continuity project management and consulting. Informatics solutions provide sample intelligence software and support laboratory workflow scheduling environmental and temperature monitoring clinical trial and consent management planning data management virtualization and visualization of sample collections. Automated Stores are stand alone systems capable of storing over 20 million samples in temperature ranges from ambient to minus eighty degrees Celsius with high throughput retrieval. Cryogenic Systems provide cryogenic storage from high efficiency liquid nitrogen vapor based freezers to fully automated systems preserving sample integrity and chain of custody. Automated Sample Tubes offer automation friendly storage tubes with coding options such as 2D coded dual coded and tri coded with external or internal threading and instruments for faster reading capping and de capping. Consumables and Instruments include a complete range of consumables such as racks tubes caps plates and foils used for storage and handling of samples in ambient to ultracold environments together with instruments for labeling bar coding capping de capping auditing sealing peeling and piercing tubes and plates. Controlled Rate Thawing Devices provide automated thawing of plasma blood stem cells and are used in cell and gene therapy applications research development clinical trials good manufacturing practices and hospital settings.

• The Multiomics segment operates as a single business unit offering genomic and other sample analysis services including gene sequencing gene synthesis and related services. It provides a comprehensive global portfolio that enables customers to select solutions for research and development challenges in areas such as cell and gene therapy antibody development and biomarker discovery. Genomic Services include Next Generation sequencing Sanger sequencing gene synthesis bioinformatics and good laboratory practice regulatory services. Sequencing services are available with standard or custom options for extraction library preparation sequencing and bioinformatics supported by Ph D level project managers offering consultation updates and post delivery assistance. Gene synthesis offerings produce a wide range of sequence lengths and structural complexity including DNA cloning gene fragment synthesis oligo synthesis and plasmid purification. The segment also adds value to drug discovery and development by expanding its portfolio to include proteomics solutions and regulated services targeting analysis of adenoassociated virus a common vector used in cell and gene therapy.

Azenta holds a strong position in the life sciences sample management and genomics markets competing with several established players. In the Sample Management Solutions segment its main competitors include Hamilton Company and Liconic AG for automation systems and Laboratory Corporation of America Holdings and Thermo Fisher Scientific for storage consumables and services. In the Multiomics segment its main competitors include BGI Genomics Co Ltd Eurofins Scientific SE GenScript Biotech Corporation Integrated DNA Technologies Inc Novogene Co Ltd and Twist Bioscience Corporation. The company differentiates itself through its broad end to end product and service portfolio its global footprint spanning approximately 95 countries its precision automation and cryogenics expertise and its ability to provide integrated solutions from sample storage to genomic analysis. These strengths allow Azenta to serve as a trusted partner for pharmaceutical biotechnology and life sciences research institutions seeking to accelerate therapy development.

Azenta serves approximately 14000 customers globally ranging from top pharmaceutical and biotechnology companies to advanced research hospitals academic and government institutions and emerging biotech start ups. While the filing does not disclose specific customer names the base includes major drug developers leading clinical research centers and prominent university laboratories. The company believes its broad customer base provides opportunities for further expansion and deeper relationships across the life sciences ecosystem.

Investment Thesis

▲ Bull case

Azenta's strategic leadership overhaul in the Multiomics segment, highlighted by the appointment of Trey Martin as President, is creating conditions for a meaningful operational turnaround that the market has yet to fully price in, despite recent stock pressure. Martin brings over three decades of life sciences leadership, including scaling integrated DNA technologies at Danaher and driving double-digit growth at Maravai LifeSciences, providing deep expertise in commercial execution, technology strategy, and global expansion—critical gaps Azenta has acknowledged in its North America Multiomics underperformance. His immediate focus on optimizing the lab footprint, right-sizing the cost structure, and strengthening commercial discipline directly addresses management’s admission that 60%-70% of the segment’s North America weakness is Azenta-specific, stemming from commercial execution and operational turnover rather than end-market deterioration. The company is already executing on these priorities, including evaluating rooftop utilization in labs and restructuring the Sanger business model to align with evolving demand, which should unlock trapped value as fixed cost absorption improves with stabilized volumes. Furthermore, the deployment of the Azenta Business System (ABS) is yielding tangible early wins, such as improving consumables and instruments on-time delivery from 15% to 70% and reducing Lightning RNA-Seq turnaround time from 20 to 5 days—now the fastest in the market—demonstrating that operational rigor is translating into measurable productivity gains. These improvements are not incremental but foundational, positioning the business to deliver higher margin and more consistent performance as volume headwinds ease, with management noting that ramp time for new sales force effectiveness is 6 to 9 months, suggesting benefits from recent commercial hires will begin to materialize in the second half of fiscal 2026.
The UK Biocentre Limited acquisition, while contributing only $1 million to second-quarter revenue, represents a strategic catalyst for Azenta’s recurring revenue growth profile that is being underappreciated due to its current minimal financial impact. Management explicitly framed the acquisition as a platform to expand Azenta’s European biorepository footprint and establish the UK Biocentre as a pan-European operational hub serving pharmaceutical, biotech, academic, and public health customers across the region—directly supporting the company’s long-range plan to scale biorepositories and increase recurring revenue mix. Biorepository solutions, which constitute roughly 40% of the Sample Management Solutions segment, delivered high single-digit growth in the quarter and are characterized by sticky, service-based revenue with higher margins and lower capital intensity compared to automated storage systems. The integration of UK Biocentre is progressing as planned, with priorities including hiring key commercial resources, achieving accreditation, and ensuring operational readiness, all of which lay the groundwork for meaningful revenue contribution in subsequent quarters. This move strengthens Azenta’s ability to offer end-to-end life cycle solutions in a life sciences research epicenter and diversifies geographic exposure away from the challenged North America Multiomics market. Given that the company is prioritizing growth in recurring-revenue businesses and has reset its long-range plan to 2029 with unchanged financial targets, the UK Biocentre acquisition is a critical enabler of that vision, with potential to drive mid- to high single-digit organic growth in SMS as biorepository expansion scales across Europe—a structural shift that could meaningfully uplift consolidated profitability over time.
Azenta’s balance sheet strength and disciplined capital allocation provide a significant cushion against near-term volatility while enabling strategic investments that could drive inflection points in growth and margin expansion, a dynamic the market is overlooking amid focus on impaired earnings. The company exited the quarter with $565 million in cash, cash equivalents, and marketable securities and zero debt, granting it substantial financial flexibility to fund organic growth initiatives, pursue disciplined M&A, and return capital to shareholders—all pillars of its unchanged capital allocation framework. Despite revising full-year guidance downward, Azenta is maintaining approximately $20 million in annual growth investments in the business, particularly in high-potential areas like gene synthesis (north of $1 billion TAM growing double-digit in key areas driven by cell and gene therapy) and automated solutions (north of $1 billion TAM growing mid- to high single-digit), signaling confidence in long-term demand trends. This commitment to growth investment, even during a downturn, reflects management’s belief that the underlying market opportunities remain strong and that temporary volume pressures are being addressed through structural fixes like the Azenta Business System and organizational redesign. Furthermore, the company generated $5 million in free cash flow during the quarter, driven by working capital improvements and increased deferred revenue—a sign of underlying business health—and guided for 10%-15% year-over-year free cash flow growth, underscoring resilience. With no debt and a growing recurring revenue base from biorepository and consumables instruments, Azenta is positioned to weather near-term softness while advancing strategic initiatives that could unlock disproportionate upside when end-market demand in North America Multiomics stabilizes, particularly as competitors may retreat from investment during this cycle.

Azenta's strategic leadership overhaul in the Multiomics segment, highlighted by the appointment of Trey Martin as President, is creating conditions for a meaningful operational turnaround that the market has yet to fully price in, despite recent stock pressure. Martin brings over three decades of life sciences leadership, including scaling integrated DNA technologies at Danaher and driving double-digit growth at Maravai LifeSciences, providing deep expertise in commercial execution, technology strategy, and global expansion—critical gaps Azenta has acknowledged in its North America Multiomics underperformance. His immediate focus on optimizing the lab footprint, right-sizing the cost structure, and strengthening commercial discipline directly addresses management’s admission that 60%-70% of the segment’s North America weakness is Azenta-specific, stemming from commercial execution and operational turnover rather than end-market deterioration. The company is already executing on these priorities, including evaluating rooftop utilization in labs and restructuring the Sanger business model to align with evolving demand, which should unlock trapped value as fixed cost absorption improves with stabilized volumes. Furthermore, the deployment of the Azenta Business System (ABS) is yielding tangible early wins, such as improving consumables and instruments on-time delivery from 15% to 70% and reducing Lightning RNA-Seq turnaround time from 20 to 5 days—now the fastest in the market—demonstrating that operational rigor is translating into measurable productivity gains. These improvements are not incremental but foundational, positioning the business to deliver higher margin and more consistent performance as volume headwinds ease, with management noting that ramp time for new sales force effectiveness is 6 to 9 months, suggesting benefits from recent commercial hires will begin to materialize in the second half of fiscal 2026.
The UK Biocentre Limited acquisition, while contributing only $1 million to second-quarter revenue, represents a strategic catalyst for Azenta’s recurring revenue growth profile that is being underappreciated due to its current minimal financial impact. Management explicitly framed the acquisition as a platform to expand Azenta’s European biorepository footprint and establish the UK Biocentre as a pan-European operational hub serving pharmaceutical, biotech, academic, and public health customers across the region—directly supporting the company’s long-range plan to scale biorepositories and increase recurring revenue mix. Biorepository solutions, which constitute roughly 40% of the Sample Management Solutions segment, delivered high single-digit growth in the quarter and are characterized by sticky, service-based revenue with higher margins and lower capital intensity compared to automated storage systems. The integration of UK Biocentre is progressing as planned, with priorities including hiring key commercial resources, achieving accreditation, and ensuring operational readiness, all of which lay the groundwork for meaningful revenue contribution in subsequent quarters. This move strengthens Azenta’s ability to offer end-to-end life cycle solutions in a life sciences research epicenter and diversifies geographic exposure away from the challenged North America Multiomics market. Given that the company is prioritizing growth in recurring-revenue businesses and has reset its long-range plan to 2029 with unchanged financial targets, the UK Biocentre acquisition is a critical enabler of that vision, with potential to drive mid- to high single-digit organic growth in SMS as biorepository expansion scales across Europe—a structural shift that could meaningfully uplift consolidated profitability over time.
Azenta’s balance sheet strength and disciplined capital allocation provide a significant cushion against near-term volatility while enabling strategic investments that could drive inflection points in growth and margin expansion, a dynamic the market is overlooking amid focus on impaired earnings. The company exited the quarter with $565 million in cash, cash equivalents, and marketable securities and zero debt, granting it substantial financial flexibility to fund organic growth initiatives, pursue disciplined M&A, and return capital to shareholders—all pillars of its unchanged capital allocation framework. Despite revising full-year guidance downward, Azenta is maintaining approximately $20 million in annual growth investments in the business, particularly in high-potential areas like gene synthesis (north of $1 billion TAM growing double-digit in key areas driven by cell and gene therapy) and automated solutions (north of $1 billion TAM growing mid- to high single-digit), signaling confidence in long-term demand trends. This commitment to growth investment, even during a downturn, reflects management’s belief that the underlying market opportunities remain strong and that temporary volume pressures are being addressed through structural fixes like the Azenta Business System and organizational redesign. Furthermore, the company generated $5 million in free cash flow during the quarter, driven by working capital improvements and increased deferred revenue—a sign of underlying business health—and guided for 10%-15% year-over-year free cash flow growth, underscoring resilience. With no debt and a growing recurring revenue base from biorepository and consumables instruments, Azenta is positioned to weather near-term softness while advancing strategic initiatives that could unlock disproportionate upside when end-market demand in North America Multiomics stabilizes, particularly as competitors may retreat from investment during this cycle.

▼ Bear case

Azenta’s persistent North America Multiomics weakness, driven by deep-seated structural issues in its Sanger business and commercial execution gaps, poses a material and sustainable threat to near- to medium-term financial performance that management may be underestimating despite leadership changes. The segment reported flat revenue on a reported basis and a 2% organic decline, with gross margin down 300 basis points year-over-year due to lower fixed cost absorption and unfavorable regional mix—directly tied to collapsing volumes in North America, where Sanger sequencing alone is declining at a steep 17% rate. Management acknowledged that 60%-70% of the underperformance is Azenta-specific, citing commercial execution shortfalls and operational turnover, yet the appointment of Trey Martin, while experienced, does not guarantee rapid remediation given the complexity of restructuring 14 legacy labs built for a larger Sanger footprint that no longer aligns with current demand. The company is transitioning to a modular product strategy and restructuring R&D, but such foundational shifts take time to yield results, and the continued pressure on fixed cost leverage means margins will remain suppressed until volume stabilizes—something not expected until at least the second half of fiscal 2026, assuming sales force ramp-up succeeds. Furthermore, competitive intensity in gene synthesis is increasing in North America, eroding any potential near-term relief, and the shift toward alternative technologies like Oxford Nanopore Technology (ONT) requires Azenta to rebalance its portfolio amid ongoing Sanger decline, adding execution risk. With long-range plan targets pushed to 2029 and Multiomics now guided to decline mid-single digits organically (versus prior low single-digit growth expectation), the segment is becoming a drag on consolidated results, and the $112.4 million goodwill impairment already taken signals that the market’s perception of its long-term value has deteriorated significantly—raising the risk of further write-downs if turnaround timelines slip.
The Sample Management Solutions segment’s reliance on capital-intensive automated and cryogenic store systems is proving to be a structural headwind that is undermining otherwise strong performance in recurring revenue lines, creating a mixed and unpredictable growth profile that increases execution risk. While biorepository solutions delivered high single-digit growth and consumables and instruments showed modest gains, these were offset by a low double-digit decline in core automated and cryogenic store products, dragging SMS organic revenue down 3% for the quarter. Management attributed this to continued softness in capital equipment demand driven by cautious customer capital spending behavior, noting that multimillion-dollar deals with biotech firms were pushed out due to funding delays or site readiness issues—not lost, but delayed—creating lumpiness in revenue recognition and forecasting difficulty. The automated stores quality remediation, while progressing, remains incomplete with three stores still under fix and an extended timeline to end of third quarter, indicating persistent operational flaws in a product line that requires high reliability. Furthermore, the company’s shift to a more modular product strategy, while sound in theory, involves discontinuing bespoke engineering and retooling R&D teams, a transition that carries inherent risks of delays, quality issues, and customer dissatisfaction during the transition period. With SMS now expected to grow only low single digits organically (versus prior mid-single-digit expectation), the segment’s growth profile is deteriorating, and its historical role as a stable cash generator is being challenged by the capital-intensive nature of its weaker-performing sub-segments, which continue to weigh on aggregate margins and growth consistency.
Azenta’s free cash flow generation, while currently positive, is increasingly dependent on working capital timing and deferred revenue rather than sustainable earnings power, raising concerns about the quality and durability of its cash flow profile amid weakening fundamentals. The company reported $5 million in free cash flow for the quarter, driven by improvements in working capital and an increase in deferred revenue—not by EBITDA expansion or net income growth, which remain negative on a non-GAAP basis at ($0.04) EPS. Adjusted EBITDA margin stood at just 5.4%, down 320 basis points year-over-year, and full-year guidance calls for a range of down approximately 125 basis points to flat versus prior year—a significant downgrade from the earlier expectation of approximately 300 basis points expansion. This margin compression reflects persistent gross margin pressures from lower volumes, fixed cost absorption issues, inventory reserves, and store rework costs, all of which suggest that the business is not generating sufficient operating leverage to self-fund growth. While the balance sheet shows strength with $565 million in cash and no debt, the company is increasingly relying on balance sheet strength to subsidize operations rather than converting profits into cash, a dynamic that could become strained if working capital improvements plateau or deferred revenue fails to convert to billed revenue. Furthermore, the delay in the B Medical Systems divestiture—now contingent on counterparty financing—means Azenta cannot yet unlock the full value of that asset or redirect proceeds toward debt reduction, share buybacks, or growth investments, leaving its capital allocation flexibility partially constrained despite the strong cash position.

Azenta’s persistent North America Multiomics weakness, driven by deep-seated structural issues in its Sanger business and commercial execution gaps, poses a material and sustainable threat to near- to medium-term financial performance that management may be underestimating despite leadership changes. The segment reported flat revenue on a reported basis and a 2% organic decline, with gross margin down 300 basis points year-over-year due to lower fixed cost absorption and unfavorable regional mix—directly tied to collapsing volumes in North America, where Sanger sequencing alone is declining at a steep 17% rate. Management acknowledged that 60%-70% of the underperformance is Azenta-specific, citing commercial execution shortfalls and operational turnover, yet the appointment of Trey Martin, while experienced, does not guarantee rapid remediation given the complexity of restructuring 14 legacy labs built for a larger Sanger footprint that no longer aligns with current demand. The company is transitioning to a modular product strategy and restructuring R&D, but such foundational shifts take time to yield results, and the continued pressure on fixed cost leverage means margins will remain suppressed until volume stabilizes—something not expected until at least the second half of fiscal 2026, assuming sales force ramp-up succeeds. Furthermore, competitive intensity in gene synthesis is increasing in North America, eroding any potential near-term relief, and the shift toward alternative technologies like Oxford Nanopore Technology (ONT) requires Azenta to rebalance its portfolio amid ongoing Sanger decline, adding execution risk. With long-range plan targets pushed to 2029 and Multiomics now guided to decline mid-single digits organically (versus prior low single-digit growth expectation), the segment is becoming a drag on consolidated results, and the $112.4 million goodwill impairment already taken signals that the market’s perception of its long-term value has deteriorated significantly—raising the risk of further write-downs if turnaround timelines slip.
The Sample Management Solutions segment’s reliance on capital-intensive automated and cryogenic store systems is proving to be a structural headwind that is undermining otherwise strong performance in recurring revenue lines, creating a mixed and unpredictable growth profile that increases execution risk. While biorepository solutions delivered high single-digit growth and consumables and instruments showed modest gains, these were offset by a low double-digit decline in core automated and cryogenic store products, dragging SMS organic revenue down 3% for the quarter. Management attributed this to continued softness in capital equipment demand driven by cautious customer capital spending behavior, noting that multimillion-dollar deals with biotech firms were pushed out due to funding delays or site readiness issues—not lost, but delayed—creating lumpiness in revenue recognition and forecasting difficulty. The automated stores quality remediation, while progressing, remains incomplete with three stores still under fix and an extended timeline to end of third quarter, indicating persistent operational flaws in a product line that requires high reliability. Furthermore, the company’s shift to a more modular product strategy, while sound in theory, involves discontinuing bespoke engineering and retooling R&D teams, a transition that carries inherent risks of delays, quality issues, and customer dissatisfaction during the transition period. With SMS now expected to grow only low single digits organically (versus prior mid-single-digit expectation), the segment’s growth profile is deteriorating, and its historical role as a stable cash generator is being challenged by the capital-intensive nature of its weaker-performing sub-segments, which continue to weigh on aggregate margins and growth consistency.
Azenta’s free cash flow generation, while currently positive, is increasingly dependent on working capital timing and deferred revenue rather than sustainable earnings power, raising concerns about the quality and durability of its cash flow profile amid weakening fundamentals. The company reported $5 million in free cash flow for the quarter, driven by improvements in working capital and an increase in deferred revenue—not by EBITDA expansion or net income growth, which remain negative on a non-GAAP basis at ($0.04) EPS. Adjusted EBITDA margin stood at just 5.4%, down 320 basis points year-over-year, and full-year guidance calls for a range of down approximately 125 basis points to flat versus prior year—a significant downgrade from the earlier expectation of approximately 300 basis points expansion. This margin compression reflects persistent gross margin pressures from lower volumes, fixed cost absorption issues, inventory reserves, and store rework costs, all of which suggest that the business is not generating sufficient operating leverage to self-fund growth. While the balance sheet shows strength with $565 million in cash and no debt, the company is increasingly relying on balance sheet strength to subsidize operations rather than converting profits into cash, a dynamic that could become strained if working capital improvements plateau or deferred revenue fails to convert to billed revenue. Furthermore, the delay in the B Medical Systems divestiture—now contingent on counterparty financing—means Azenta cannot yet unlock the full value of that asset or redirect proceeds toward debt reduction, share buybacks, or growth investments, leaving its capital allocation flexibility partially constrained despite the strong cash position.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password